Table IV.
Treatment-related adverse events (worst grade per patient; n = 34)
| NCI-CTCAE grade |
||||
|---|---|---|---|---|
| 1/2 |
3 |
|||
| n | % | n | % | |
| Alanine aminotransferase increase | - | - | 1 | 2.9 |
| Anemia | 1 | 2.9 | 1 | 2.9 |
| Asthenia | 6 | 17.6 | - | - |
| Fever | 1 | 2.9 | - | - |
| Intolerance to antiemetics | 1 | 2.9 | - | - |
| Mucositis | 3 | 8.8 | 2 | 5.9 |
| Myalgia | 1 | 2.9 | - | - |
| Nausea/vomiting | 12 | 35.3 | 5 | 14.7 |
| Neutropenia | 5 | 14.7 | 1 | 2.9 |
| Pancreatitis | 1 | 2.9 | - | - |
| Phlebitis | 1 | 2.9 | - | - |
| Sensorial peripheral neuropathy | 2 | 5.9 | - | - |
| Thrombocytopenia | 1 | 2.9 | - | - |
NCI-CTCAE = National Cancer Institute Common Terminology Criteria for Adverse Events.